The Ribose-Nucleic Acid (RNA)-Based Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report
According to The Business Research Company’s Ribose-Nucleic Acid (RNA)-Based Therapeutics Global Market Report 2024, The ribose-nucleic acid (RNA)-based therapeutics market size has grown strongly in recent years. It will grow from $14.54 billion in 2023 to $15.79 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to investment and funding growth, the discovery of RNA interference (RNAi), clinical successes of antisense oligonucleotides (ASOs), regulatory support and frameworks, and collaborations, and partnerships.
The ribose-nucleic acid (RNA)-based therapeutics market size is expected to see strong growth in the next few years. It will grow to $22.30 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to the expansion of indications, rising market demand and adoption, regulatory support, integration of AI and machine learning, and emerging applications in rare diseases. Major trends in the forecast period include advanced delivery systems, multi-target RNA therapeutics, customized RNA therapies, regulatory advancements, and commercialization and market growth.
The increasing prevalence of cancer is expected to propel the growth of the ribose-nucleic acid (RNA)-based therapeutics market going forward. Cancer refers to a condition where abnormal cells grow and spread uncontrollably, potentially leading to death if untreated. The prevalence of cancer is due to an aging population, lifestyle changes, greater exposure to risks, and better detection methods. RNA-based therapeutics offer a promising avenue for cancer treatment by directly targeting the genetic and molecular mechanisms of cancer. For instance, in August 2023, according to the Australian Institute of Health and Welfare, an Australia-based government administration for health, around 151,000 individuals were diagnosed with cancer (excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin) in 2021, which is expected to reach 185,000 in 2030. Therefore, the increasing prevalence of cancer is driving the ribose-nucleic acid (RNA)-based therapeutics market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp
The ribose-nucleic acid (RNA)-based therapeutics market covered in this report is segmented –
1) By Type: RNA Interference (RNAi), RNA Antisense
2) By Technology: Enabling Technology, Enabled Technology
3) By Therapeutic Area: Oncology, Genetic Disorder, Opthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas
4) By End User: Research Institutes, Hospitals And Clinics
Major companies operating in the ribose nucleic acid (RNA)-based therapeutics market are focused on developing innovative medication solutions, such as messenger RNA (mRNA)-based booster vaccines, to enhance the effectiveness of immunization, address emerging viral variants, and improve the overall durability of vaccine-induced immunity. An mRNA-based booster vaccine uses messenger RNA to prompt cells to create a protein that enhances the body’s immune response against a particular pathogen. For instance, in June 2023, Gennova Biopharmaceuticals Ltd., an India-based pharmaceutical company, launched GEMCOVAC-OM, a India’s first mRNA booster vaccine specifically targeting the Omicron variant of COVID-19. This booster is essential due to the limited efficacy of the original vaccines against Omicron. Utilizing mRNA technology, GEMCOVAC-OM boosts immunity and offers enhanced protection against the evolving virus.
The ribose-nucleic acid (rna)-based therapeutics market report table of contents includes:
1. Executive Summary
2. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Characteristics
3. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Trends And Strategies
4. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market – Macro Economic Scenario
5. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Size and Growth
.
.
.
32. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Competitive Benchmarking
33. Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market
35. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
